This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pruthi, R. S. Articles by Wallen, E. Search for Related Content PubMed PubMed Citation Articles by Pruthi, R. S. Articles by Wallen, E.

Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy

Authors' Affiliations: ¹ Division of Urologic Surgery, ² Department of Biostatistics, and ³ Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Requests for reprints: Raj S. Pruthi, Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB#7235, Chapel Hill, NC 27599. Phone: 919-966-2574; Fax: 919-966-0098; E-mail: rpruthi{at}med.unc.edu.

Objectives: Recent evidence has shown that cyclooxygenase-2 (COX-2) inhibitors have potent antitumor activity in prostate cancer both in vitro and in vivo. However, human trials are absent. This study evaluated the efficacy of the COX-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after radiation therapy (X-ray therapy or XRT) or radical prostatectomy.

Methods: Forty patients who had biochemical relapse after XRT or radical prostatectomy were treated with celecoxib 400 mg twice per day. Follow-up PSA levels were obtained at 3, 6, 12, and 18 months and subsequently every 6 months thereafter. Data were evaluated by calculating PSA doubling times and by calculating the slope of the curve of log(PSA) versus time to assess rate of PSA increase before and after celecoxib treatment for each patient.

Results: Thirty-six of 40 (90%) patients had a slowing effect on their rate of PSA after 3 months, including 11 of 40 with a decline and 8 of 40 with stabilization of PSA. Short-term responses at 3 months continued at 6, 12, 18 months. Comparison of rate of PSA increase before versus after celecoxib treatment showed significant flattening of slope of log(PSA) versus time from pretreatment for each of the time points. There was no significant change in testosterone levels, suggesting an androgen-independent mechanism.

Conclusions: COX-2 inhibitors may have an effect on serum PSA levels in patients with biochemical progression after XRT or radical prostatectomy. These results suggest that COX-2 inhibitors may help delay or prevent disease progression in these patients and thereby help extend the time until androgen deprivation therapy.

This article has been cited by other articles:

				P. SOORIAKUMARAN, H. M. COLEY, S. B. FOX, P. MACANAS-PIRARD, D. P. LOVELL, A. HENDERSON, C. G. EDEN, P. D. MILLER, S. E.M. LANGLEY, and R. W. LAING A Randomized Controlled Trial Investigating the Effects of Celecoxib in Patients with Localized Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1483 - 1488. [Abstract] [Full Text] [PDF]

				P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, and H.M. COLEY A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer Cancer Genomics Proteomics, March 1, 2009; 6(2): 93 - 99. [Abstract] [Full Text] [PDF]

				S. J. Assinder, Q. Dong, H. Mangs, and D. R. Richardson Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-{beta} Pathways in Prostate Cancer Mol. Pharmacol., March 1, 2009; 75(3): 429 - 436. [Abstract] [Full Text] [PDF]

				J. Jayachandran and S. J. Freedland Prevention of Prostate Cancer: What We Know and Where We Are Going American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189. [Abstract] [PDF]

				S. Kesari, D. Schiff, J. W. Henson, A. Muzikansky, D. C. Gigas, L. Doherty, T. T. Batchelor, J. A. Longtine, K. L. Ligon, S. Weaver, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Neuro-oncol, January 1, 2008; 10(3): 300 - 308. [Abstract] [Full Text] [PDF]

				C. Van Waes Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082. [Abstract] [Full Text] [PDF]

				F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044. [Abstract] [Full Text] [PDF]